Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb;30(1):75-101.
doi: 10.1016/j.iac.2009.10.001.

Pathogenesis and management of graft-versus-host disease

Sung W Choi  1 , John E Levine, James L M Ferrara
Affiliations
Review

Pathogenesis and management of graft-versus-host disease

Sung W Choi et al. Immunol Allergy Clin North Am. 2010 Feb.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is an important therapeutic option for various malignant and nonmalignant conditions. As allogeneic HCT continues to increase, greater attention is given to improvements in supportive care, infectious prophylaxis, immunosuppressive medications, and DNA-based tissue typing. However, graft versus host disease (GVHD) remains the most frequent and serious complication following allogeneic HCT and limits the broader application of this important therapy. Recent advances in the understanding of the pathogenesis of GVHD have led to new approaches to its management, including using it to preserve the graft versus leukemia effect following allogeneic transplant. This article reviews the important elements in the complex immunologic interactions involving cytokine networks, chemokine gradients, and the direct mediators of cellular cytotoxicity that cause clinical GVHD, and discusses the risk factors and strategies for management of GVHD.

PubMed Disclaimer

Figures

Figure 1
Figure 1. From discovery to validation of plasma biomarkers of acute graft versus host disease
(This research was originally published in Blood. [115] Panel A shows the heatmap of proteins levels measured sequential ELISA in the discovery set samples. Samples from 21 GVHD– patients (left) and 21 GVHD+ patients (right) are represented. Eleven proteins gave a P values for differences between GVHD+ and GVHD– patient plasma< 0.05. Panel B shows the receiver operating characteristic (ROC) curves of four individual discriminator proteins and the composite panel in the training set. Individual ROC curves for IL-2Ra,TNFR1, HGF, and IL-8 and the composite panel.
See this image and copyright information in PMC

References

    1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667–674. - PubMed
    1. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–170. - PubMed
    1. Reddy P, Arora M, Guimond M, et al. GVHD: a continuing barrier to the safety of allogeneic transplantation. Biol Blood Marrow Transplant. 2008;15(1 Suppl):162–168. - PMC - PubMed
    1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966–67;62:21–78. - PubMed
    1. Korngold R, Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale RP, Champlin R, editors. Progress in Bone Marrow Transplant. New York: Alan R, Liss, Inc.; 1987. pp. 213–218.

MeSH terms